Visfatin concentrations in obese patients in relation to the presence of newly diagnosed glucose metabolism disorders

Endokrynologia Polska

Volumn 66, Issue 2, 2015, Pages 108-113

  Kamińska, Anna ^a   Kopczyńska, Ewa ^a   Bieliński, Maciej ^a   Borkowska, Alina ^a   Junik, Roman ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Diabetes; Obesity; Prediabetes; Visfatin

Indexed keywords

C PEPTIDE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; THYROTROPIN; TRIACYLGLYCEROL; URIC ACID; CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; FEMALE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HIP CIRCUMFERENCE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; THYROTROPIN BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; BLOOD; ENZYMOLOGY; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; CYTOKINES; FEMALE; GLUCOSE METABOLISM DISORDERS; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; TRIGLYCERIDES; YOUNG ADULT;

EID: 84929415999     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: 10.5603/EP.2015.0016     Document Type: Article

References (30)

1. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 21: 426-430.
2. Samal B, Sun Y, Stearns G et al. Cloning and characterization of cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994; 14: 1431-1437.
3. Rongvaux A, Shea RJ, Mulks MH et al. Pre-B-cell colony - enhancing factor, whose expression is upregulated in activated lymphocytes, is nicotinamide phosphoribosylotransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002; 32: 3225-3234.
4. Haider DG, Schindler K, Schaller G et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578-1581.
5. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J et al. Serum concentration of visfatin in obese women. Metabolism 2007; 56: 1131-1134.
6. Chang YH, Chang DM, Lin KC et al. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011; 27: 515-527.
7. Fukuhara A, Matsuda M, Nishizawa M et al. Retraction. Science 2007;318: 565.
8. McGee KC, Harte AL., da Silva NF et al. Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFκβ and JNK in Human Abdominal Subcutaneous Adipocytes. PLoS one 2011; 6: e 20287
9. Kamińska A, Kopczyńska E, Bronisz A et al. An evaluation of visfatin levels in obese subjects. Endokrynol Pol 2010; 61: 169-173.
10. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
11. Field AE, Coakley EH, Must A et al. Impact of overweight on the risk of developing chronic diseases during a 10-year period. Arch Intern Med 2001; 161: 1581-1586.
12. Colagiuri S. Diabesity: therapeutic options. Diabetes Obesity Metab 2010; 12: 463-473.
13. Wang C, Guan Y, Yang J. Cytokines in the progression of pancreatic b-cell dysfunction. Int J Endocr 2010: 515136 (published online 2010 Nov 14).
14. Haider DG, Schaller G, Kapiotis S et al. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49: 1909-1914.
15. Kowalska I, Karczewska-Kupczewska M, Adamska A et al. Serum visfatin in differentially regulated by insulin and free fatty acids in healthy men. J Clin Endocrinol Metab 2013; 98: E293-297.
16. Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M et al. Serum visfatin increases with progressive β-cell deterioration. Diabetes 2006; 55: 2871-2875.
17. Cheng Q, Dong W, Qian L et al. Visfatin inhibits apoptosis of pancreatic β-cell line, MIN 6, via the mitogen-activated protein kinase/phosphoinositide 3-kinase pathway. J Mol Endocr 2011; 47: 13-21.
18. Hofsr D, Ueland T, Hager H et al. Inflammatory mediators in morbidly obese subjects; associations with glucose abnormalities and changes after oral glucose. Eur J Endocrinol 2009; 161: 451-458.
19. Jian WX, Luo TH, Gu YY et al. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet Med 2006; 23: 967-973.
20. Dogru T, Sonmez A, Tasci I et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diab Res Clin Pract 2007; 76: 24-29.
21. Chen MP, Chung FM, Chang DM et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299.
22. Shaker O, El-Shehaby A, Zakaria A et al. Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver. Clin Biochem 2011; 44: 1457-1463.
23. Hajianfar H, Bahonar A, Entezari MH et al. Lipid profiles and serum visfatin concentration in patients with type II diabetes in comparison with healthy controls. Int J Prev Med 2012; 3: 326-331.
24. Esteghamati A, Alamdari A, Zandieh A et al. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diab Res Clin Pract 2011; 91: 154-158.
25. Li L, Yang G, Li Q et al. Changes and relations of circulating visfatin, apelin and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Diabetes 2006; 114: 544-548.
26. Olszanecka-Glinianowicz M, Kocelak P, Janowska J et al. Plasma visfatin and tumor necrosis factor-alpha (TNF-α) levels in metabolic syndrome. Kardiol Pol 2011; 69: 802-807.
27. Sun G, Bishop J, Khalili S et al. Serum visfatin concentrations are positively correlated with triacyloglicerols and down-regulated by overfeeding in healthy young men. Am J Clin Nutr 2007; 85: 399-404.
28. Eckel RH. The metabolic syndrome. In: Jameson JL, ed. Harrison's Endocrinology. Mc Graw Hill Medical, 2nd edition 2010: 261-262.
29. de Luis DA, Sagrado MG, Conde R et al. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients. Nutrition 2008; 24: 517-521.
30. Ostrowska Z, Ziora K, Oświęcimska J et al. Bone metabolism, osteoprotegerin, receptor activator of nuclear factor κ β ligand and selected adipose tissue hormones in girls with anorexia nervosa. Endokrynol Pol 2014; 65: 33-39.